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Abstract
Randomized placebo-controlled trials have reported efficacy of methylphenidate (MPH) for
Attention-deficit/hyperactivity disorder (ADHD); however, selection biases due to strict entry
criteria may limit the generalizability of the findings. Few ecologically valid studies have
investigated effectiveness of MPH in representative clinical populations of children. This
independently funded study aims to describe treatment responses and their predictors dur-
ing the first 12 weeks of MPH treatment using repeated measurements of symptoms and
adverse reactions (ARs) to treatment in 207 children recently diagnosed with ADHD. The
children were consecutively included from the Child and Adolescent Mental Health Centre,
Mental Health Services, The Capital Region of Denmark. The children (mean age, 9.6 years
[range 7–12], 75.4% males) were titrated with MPH, based on weekly assessments of
symptoms (18-item ADHD-rating scale scores, ADHD-RS-C) and ARs. At study-end 187
(90.8%) children reached a mean end-dose of 1.0 mg/kg/day. A normalisation/borderline
normalisation on ADHD-RS-C was achieved for 168 (81.2%) children on the Inattention
and/or the Hyperactivity-Impulsivity subscale in week 12, and 31 (15.0%) children were non-
responders, which was defined as absence of normalisation/borderline normalisation (n =
19) or discontinuation due to ARs (n = 12), and eight (3.8%) children dropped out from fol-
low-up. Nonresponders were characterised by more severe symptoms of Hyperactivity-
Impulsivity and global impairment before the treatment. ARs were few; the most prominent
PLOS ONE







Citation: Kaalund-Brok K, Houmann TB, Hebsgaard
MB, Lauritsen M-BG, Lundstrøm LH, Grønning H,
et al. (2021) Outcomes of a 12-week ecologically
valid observational study of first treatment with
methylphenidate in a representative clinical sample
of drug naïve children with ADHD. PLoS ONE
16(10): e0253727. https://doi.org/10.1371/journal.
pone.0253727
Editor: Andrea Martinuzzi, IRCCS E. Medea, ITALY
Received: May 17, 2020
Accepted: June 4, 2021
Published: October 21, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0253727
Copyright: © 2021 Kaalund-Brok et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The study measured
the outcomes of a 12-week ecologically valid
observational study of first treatment with
were appetite reduction and weight loss. A decrease in AR-like symptoms during the treat-
ment period questions the validity of currently available standard instruments designed to
measure ARs of MPH. This ecologically valid observational study supports prior randomized
placebo-controlled trials; 81.2% of the children responded favourably in multiple domains
with few harmful effects to carefully titrated MPH.
Clinical trial registration: ClinicalTrials.gov with registration number NCT04366609.
Introduction
Attention deficit/hyperactivity disorder (ADHD) as defined in the DSM-IV/-5 (Diagnostic
and Statistical Manual of Mental Disorders, DSM) [1] is a heterogeneous neurodevelopmental
disorder characterised by pervasive and impairing symptoms of inattention and/or hyperactiv-
ity and impulsivity with onset of symptoms before age 7 (DSM-IV) or age 12 (DSM-5). The
syndrome of Hyperkinetic disorder based on the International Classification of Diseases and
Related Health Problems (ICD-10) [2] is roughly equivalent to the combined presentation of
ADHD as per the DSM-IV/-5, and regardless of definitions, the ADHD syndromes show high
rates of persistence into adulthood [3, 4]. The mean estimated worldwide prevalence of
ADHD is 3.4% (CI 95% 2.6 to 4.5) in the general population of children and adolescent, mak-
ing it the most common neurodevelopmental disorder in youth [5]. ADHD has a polygenic
and multifactorial aetiology that is only partly understood [6].
The National Institute for Health and Care Excellence (NICE; United Kingdom) recom-
mends methylphenidate (MPH) as a first-line pharmacological treatment of ADHD in chil-
dren [7], and recent guideline strongly recommend parent management training and other
behavioural treatments within family and school along with medication [8, 9]. MPH is a cen-
tral nervous system stimulant that has been used for treatment of ADHD in youth since the
1960s [10]. Although its mechanism of action is not completely understood, MPH inhibits the
dopamine and the norepinephrine transporters [11], primarily resulting in increased extracel-
lular levels of dopamine in the brain [12, 13].
Several meta-analyses of the short-term efficacy of immediate release MPH (IR-MPH) in
randomized placebo-controlled trials have reported large effect sizes (range from 0.54 to 1.78)
on ADHD core symptoms, when effects are measured as differences in endpoint or change in
scores of parent-rated and teacher-rated ADHD symptoms and behaviours [14, 15]. A review
of treatments for ADHD in adolescents aged 12–18 years found large effects for stimulants
(extended-release MPH and amphetamine) describing a mean change in absolute symptoms
score ranging from 10 to 18 points on the clinician-rated, 18-item-ADHD-rating-scale
(ADHD-RS-C, range 0–54 [16, 17]). Also, two network metanalyses have reported favorable
efficacy of MPH compared with placebo in randomized placebo-controlled trials [18, 19].
Beneficial effects of IR-MPH have been demonstrated in several domains including
improvements in ADHD symptoms and behaviours at home and in school [14, 20], cognitive
functions [21], classroom behaviour, and academic performance [22], although a recent meta-
analysis found only small effects on school performance [23]. The primary measure of MPH
efficacy in randomized controlled trials (RCTs) is usually the endpoint or change in scores of
total ADHD symptoms, and clinically meaningful response is generally considered to be a
within-group symptom reduction of 25% [24] or 30% [25] on ADHD-RS (corresponding to
10–15 absolute points).
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However, there is no generally accepted definition of the clinically significant response to
treatment for ADHD, and the response rates obviously vary with the psychometric instrument,
the informant, and the defined response criteria [15, 24]. In one RCT, the response was
defined as a 40% or more decrease in sum scores in ADHD-RS-C after 6 weeks of treatment
[26], resulting in a response rate of 64% in youth patients treated with MPH for the first time.
Generally, adverse reactions (ARs) to MPH treatment are poorly described in the literature,
partly due to huge variations in the definitions and the instruments for measurement of ARs
[27]. A review of ARs associated with MPH in short-term studies showed rates of loss of appe-
tite of 3 to 56%, poor sleep of 9 to 64%, headache of 2 to 33%, and abdominal pain of 4 to 19%
[27]. Another review of ARs induced by MPH in long-term studies with a duration of one to
two years reported discontinuation rates due to ARs of 8 to 15%, and incidences of any ARs of
85 to 89%, loss of appetite 14 to 19%, poor sleep 15 to 19%, headache 25 to 30%, and abdominal
pain 8 to 11% [28]. Although the efficacy and safety of MPH is well documented in placebo-
controlled RCTs and meta-analyses of RCTs, less is known about the “real world” effectiveness
of MPH for treatment of heterogeneous samples of children with ADHD in service of child
and adolescent mental health. The RCTs of MPH may be biased by selection according to the
studies’ inclusion and exclusion criteria (typically excluding comorbidity), the patients’ will-
ingness to participate, and the clinicians’ willingness to allocate patients to randomised inter-
vention studies. The limited generalizability of the evidence from the RCTs, including the risk
of selection bias, calls for more naturalistic observational studies of the effectiveness of MPH in
representative clinical samples of children with ADHD, treated in routine settings, including
all MPH-treated children regardless of ADHD severity, ADHD subtype and comorbidity [29].
In preparation for the analysis of the present study, we systematically searched PubMed for
naturalistic observational clinical studies of MPH treatment of children with ADHD including
studies from the start of the PubMed database from 1987 to January 6, 2020 (S1 Fig, PRISMA
flow chart; S1 Table, criteria for literature search). A total of 43 publications covering 30 natu-
ralistic observational MPH studies were identified of MPH-free (no MPH treatment at the time
of inclusion) children aged 7–12 years and of these were 21 publications covering 17 studies of
MPH naïve children aged 6–18 years, and of these were 11 studies with 14 publications with
subgroup analyses (e.g. outcomes of specific genotypes) or specific neurocognitive outcome
[30–43] (S2 Table, included studies). The 11 studies of MPH naïve children included a total of
n = 1537 patients (51–280 per study) with a mean age of 9.3 [mean range 8.0–10.3] years. The
mean end-dose of MPH was 0.80 mg/kg/day [range 0.50–1.06]. The mean follow-up time was
9.5 weeks [range 4–24], with a number of follow-up points in time varying from 1 to 6 weeks.
Only nine studies monitored the response to MPH using well-known psychometric instru-
ments: DuPaul’s ADHD Rating Scale rated by parents (ADHD-RS-P, [range 0–54]) [16] and
rated by clinicians (ADHD-RS-C [range 0–54]) [17], the revised Conner’s Parent Rating Scale
(CPRS-R, [range 0–144]) [44], Swanson Nolan Pelham version IV scale (SNAP-IV, [range
0–60] [45], Test of Variables of Attention (TOVA) [46], Clinical Global Impression Improve-
ment (CGI-I, [range 1–7]), and/or CGI Severity (CGI-S, [range 1–7]) [47]. Nine studies (11
publications) a priori defined a response criterion for symptom reduction measured with vali-
dated instruments and the reported response rates varied from 15.1% to 81.5% [30–33, 35, 37,
41–43]. The mean reduction of ADHD core symptoms (in percentage of symptom level at
entry) varied from 23.8% to 62.7% [31–33, 35, 39, 40]. Only one study divided ADHD-RS-P
and ADHD-RS-C into subscales of Inattention [range 0–27] and Hyperactivity-Impulsivity
[range 0–27], and the mean reductions were 41.4% to 59.3% on the Inattention and 47.3% to
66.0% on the Hyperactivity-Impulsivity subscales, respectively [33]. Seven of the 11 studies
apparently monitored ARs [31, 33, 34, 36, 39, 48], but the reporting was incomplete and thus
difficult to summarise. Reduced appetite was present in roughly 25–66% of patients [33, 34,
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39, 42] using Barkley’s Stimulant Side Effect Rating Scale [49] (BSSERS) and severe appetite
reduction in 21.3% of patients [48]. Weight loss was reported in 34% of patients [39]. Intolera-
ble ARs (defined by each study) were found in 8% of patients [31]. The vast majority of
patients (75–82%) had one or more ARs during the treatment period [33, 34]. One study mea-
sured 82.8% of patients having more than one AR during the treatment period while only
4.5% of patients withdrew from the study due to ARs [33].
In summary, there is no consensus on the definition of a clinically significant response to
MPH treatment, and the reported response rates, and rates of ARs apparently vary with patient
sample, study design, and the applied psychometric instruments and informants.
The overall objective of this ecologically valid prospective observational intervention study
was to characterise the beneficial effects and ARs of IR-MPH treatment in a clinical sample of
MPH naïve children recently diagnosed with ADHD and offered an individually titrated dos-
ing of IR-MPH. The specific aims were to (a) describe the treatment response during the first
12 weeks after initiation of IR-MPH treatment based on weekly clinician-rated ADHD core
symptoms and behaviours, the rate of normalisation/borderline normalisation of ADHD core
symptoms, ARs, daily and social functioning, and indices of sustained attention; (b) provide
information about the predictive value of clinical characteristics at entry (sex, age group, global
severity of psychiatric disorder, psychiatric comorbidity, and subtype of ADHD diagnoses) for
these outcomes; and (c) determine the end-dose of IR-MPH.
Materials and methods
Participants
The study included MPH naïve boys and girls aged 7–12 years with a recent ICD-10 diagnosis
of hyperkinetic disorder (F90.0–90.9) or attention deficit disorder without hyperactivity
(F98.8) and clinical indication for treatment with IR-MPH. Patients referred to the Child and
Adolescent Mental Health Centre, Mental Health Services (The Capital Region of Denmark)
in the period from 1st of May 2012 to 1st August 2014, and who were suspected of having
ADHD were consecutively screened for study eligibility.
The exclusion criteria were mental retardation (ICD-F70.X or IQ < 70), previous treatment
with drugs metabolised by carboxylesterase 1 (CES1) (see below); e.g., MPH, severe comorbid
psychiatric or somatic disease that resulted in contraindication for treatment with MPH (e.g.,
schizophrenia or cardiac disease), language barriers, and lack of informed consent.
Study design
The study was a prospective, noncontrolled intervention study. It is a part of the Danish INDI-
CES study as work package six (INDIvidualised drug therapy based on pharmacogenetics:
focus on personalising the treatment of drugs metabolised by carboxylesterase 1 (CES1) [50].
Study protocol is available (S1 and S2 Files). The study followed the protocol, and the only
deviations from the protocol was that we did not include CGI-Efficacy [47] and ASK-ME atti-
tude [51].
Diagnostic evaluation
The diagnostic procedure was performed in accordance with the Danish “National clinical
guideline for the assessment of ADHD in children and adolescents” [52]. A diagnosis of
ADHD was posed after a thorough assessment including clinical observations and examina-
tions of the children using the following instruments: Schedule for Affective Disorders and
Schizophrenia for School-Age Children, Present and Lifetime Version [53], ADHD-RS-P and
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ADHD-RS-T [16, 54, 55], parent rated Child Behaviour Checklist and teacher rated Teacher
Report Form [56–58], Weiss Functional Impairment Rating Scale–Parent version (WFIRS-P)
[59, 60], and TOVA [46, 61]. Experienced medical doctors and psychologists, all trained in the
instruments used in this study, conducted all assessments.
As a part of the routine clinical care, a senior consultant in child and adolescent psychiatry
confirmed the ADHD diagnosis, any psychiatric comorbid disorders, and the indication for
treatment with IR-MPH. Patients were consecutively included in the study after their parents
had given informed consent to participate in the study.
Administration of IR-MPH treatment
According to the Danish guidelines for treatment of ADHD, MPH is the first-line drug when
pharmacological treatment is indicated. The Danish guidelines are similar to The NICE guide-
lines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until
no further effect is measured on a standard ADHD rating scale, or the appearance of intolera-
ble ARs, or a maximum dose of 2.1 mg/kg/day [7, 62]. Based on these guidelines, we developed
an enhanced IR-MPH-treatment manual for the present study with weekly telephone-based
ratings and monthly clinical assessments of symptom change and the presence of ARs to allow
for an individually titrated optimal dosing of IR-MPH. The study used IR-MPH in the form of
Medikinet1 5, 10 and 20 mg because of the option to split the tablet. It was the children’s regu-
lar clinicians who decided to treat each patient with IR-MPH as a part of the routine care. The
initial dose was 2.5 or 5 mg IR-MPH depending upon a patient’s weight (</> 30 kg). Tablets
were given two or three times a day as determined by each patient’s needs and was adminis-
tered of parents and teachers. The weekly individually dose increment of 2.5 or 5 mg IR-MPH
per dose continued until a clinically significant response, defined as normalisation/borderline
normalisation on ADHD-RS-C was achieved, ARs prohibited further up-titrations of the total
daily dose of IR-MPH, or the maximum dose was reached. Some circumstances allowed
patients to change to other MPH formulations (Motiron1 in the event of lactose intolerance
or extended-release-MPH if patients were non-compliant or had ARs due to IR-MPH).
Patients were excluded from further study assessments if their medication changed to a non-
MPH preparation (e.g., atomoxetine) or if they were noncompliant with the treatment.
The assessment programme
The patients were enrolled in the study for a 12-week study period from 1st of May 2012 to 1st
August 2014. After enrolment, the initial assessments were done immediately before initiation
of IR-MPH in week 0. The clinical investigator (KKB, TH, and MH) undertook the weekly
evaluation of ADHD core symptoms and ARs using the ADHD-RS-C and the clinician-rated
BSSERS-C. The weekly evaluations were based on telephone interviews with the parent in
week 1, 2, 3, 5, 6, 7, 9, 10, 11, and on more thorough clinical evaluation at baseline (week 0)
and in week 4, 8, and 12, including interviews with the parents about the children’s daily func-
tions and symptoms, clinical observation and physical examination of the patients, and parent-
and teacher-rated ADHD core symptoms (ADHD-RS-P and ADHD-RS-T). The clinical inves-
tigator and the children’s regular clinicians who all used the ADHD-RS-C in week 0 and 12
conducted consensus ratings of the children’s ADHD core symptoms. Decisions about
changes in IR-MPH dosing or discontinuation due to ARs were made in collaboration with
the children’s’ regular clinicians and the families at the study site. The clinical investigator and
the children’s regular clinicians where not blind to the dosage of IR-MPH, as they collaborated
to personalise the dosing of MPH based on the weekly assessments of the ADHD core symp-
toms and ARs for the treatment of each child.
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The same pair of the clinical investigator and the child’s regular clinician followed the same
patient over 12 weeks (the first author was the clinical investigator and rater in 71% of cases).
In weeks 0 and 12, each rater performed an independent rating of the ADHD-RS-C before
they agreed on a consensus rating. The two independent ratings were used for calculation of
the interrater reliability for the pair at each time point using the intraclass correlation coeffi-
cient (ICC). The mean of the ICCs was calculated for each pair across time points. The mean
ICCs ranged from 0.72 to 0.99 (mean of ICC = 0.90). If any disagreement was found, the single
items of ADHD-RS-C were discussed until consensus was reached. Consensus ratings of
ADHD-RS-C scores in week 0 and 12 were measured to set an individual standard for the clin-
ical investigator ratings in week 1 to 11. None of the clinicians were blinded to evaluation of
the treatment and changes of the treatment with MPH.
Assessment instruments
ADHD-RS-scales. The primary outcome of the 12-week IR-MPH-treatment was mea-
sured with the ADHD-RS scales [16, 17, 54, 55]. The ADHD-RS-P and the ADHD-RS-T each
consist of nine questions of inattention, nine questions of hyperactivity and impulsivity, and
six questions of conduct problems evaluated on a four-point Likert scale from 0 (none = never
or rarely) to 3 (severe = very often). The 18-item, clinician-rated ADHD-RS (ADHD-RS-C) is
identical to the ADHD-RS-P and ADHD-RS-T subscales measuring Inattention and Hyperac-
tivity-Impulsivity, whereas Conduct problems are not scored [17]. ADHD-RS-P and
ADHD-RS-T have previously been validated in a Danish general population-based sample
(n = 865 children) [55], and the standardised scores (t-scores) stratified for each sex and age
group (7–9 and 10–12 years) were used to delineate the cut-off for normalisation (� 60 t-
scores) or borderline normalisation (60–70 t-scores) on the clinician-rated ADHD-RS-C scores
of Inattention and of Hyperactivity-Impulsivity in the present study. High correlations
between ADHD-RS-C and ADHD-RS-P have been documented [63]. In the present study,
ADHD-RS-C scores were determined using all available information including interviews
with the parents, the parent- and teacher-rated ADHD-RS scores, psychiatric assessment, and
observation of the children. The ADHD-RS-C scores were used to describe change in symp-
toms (sum scores) and proportions of children normalised (Nor) or borderline normalised
(Bnor); any treatment response was defined as Nor or Bnor (Nor/Bnor).
Clinical Global Impression Severity scale (CGI-S). The clinician-rated CGI-S (English
version) is a seven-point Likert scale, rated 1 (normal, not ill at all) to 7 (among the most
extremely ill patients), used to measure the global severity of symptoms and functional impair-
ments of mental health disorder including ADHD and psychiatric comorbidities [47]. Consen-
sus ratings were performed in week 0 and 12. A beneficial symptom reduction was defined by
a CGI-S score of 1 or 2 (normal, not ill at all or borderline ill) based on a definition from
another study [32].
Clinical Global Impression Improvement (CGI-I). The clinician-rated CGI-I (English
version) is also a seven-point Likert scale rated from 1 (very much improved) to 7 (very much
worse) [47]. Consensus ratings were performed in week 12. A beneficial symptom reduction
was defined by a CGI-I score of 1 or 2 (very much improved or much improved) based on a def-
inition from other studies [35, 41, 42].
Test of Variables of Attention (TOVA)
TOVA is a computerized, continuous performance test and is validated to evaluate the objec-
tive response to the treatment of ADHD [46, 61, 64, 65]. TOVA was administrated in week 0
and 12, and number of commission errors (response to non-target), number of omission
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errors (non-response to target), the response time in microseconds, and the variability of
response time in correct responses to target were measured over the 21.6-minute-long test
used as total raw scores. The study used version 7.3 and 8.0 of TOVA [66, 67]. Consistently,
IR-MPH was dosed at 1 p.m. and TOVA was performed at 2 p.m. [68] to ensure an equal and
sufficient exposure of IR-MPH at the week 12-assessment (maximal plasma concentration is
achieved 1–2 hours after administration of IR-MPH [69]). In week 0 and 12, total raw scores
were converted to z-scores based on mean and standard deviation of week 0 raw scores due to
the lack of standard of TOVA for Danish children.
Weiss Functional Impairment Rating Scale—Parent version (WFIRS-P). WFIRS-P
(Danish version) is a parent-rated questionnaire, with 50 questions about a child’s daily and
social functioning in six different domains of a child’s life: family (10 items), learning and school
(10 items), activities of daily living (10 items), self-concept (3 items), social activities (7 items),
and risky activities (10 items) [59, 60, 70]. It is evaluated on a four-point Likert scale from 0
(never or not at all) to 3 (very often or very much). Index scores of WFIRS-P were measured in
week 0 and 12 [71]. Single item scores = 2–3 signal impairment (> 2 SD) [59, 60, 70]. If the par-
ent-reported scores were missing for a single item on a subscale (maximum 1 item) we still cal-
culated the index score as the sum-score divided by the number of items that were scored.
Barkley’s Stimulant Side Effect Rating Scale (BSSERS-C). ARs were measured by the
clinical investigator using the BSSERS-C (Danish version) [49]. It consists of 17 effect items
rated by the clinician, based on information from patients, parents, and clinical observations:
insomnia, nightmares, staring, talks less, disinterested in others, reduced appetite, irritable,
stomachaches, headaches, drowsiness, sadness, prone to crying, anxious, nail biting, euphoria,
dizziness, and tics/nervous movements. BSSERS-C is a 10-point Likert scale rated from 0
(problem absent) to 9 (problem evokes serious impairment). A manual for interviewing and rat-
ing using BSSERS-C was elaborated for the study, anchoring the 10-point problem scores (e.g.,
specifying the time to fall asleep when scoring insomnia). The BSSERS-C was scored before
initiation of IR-MPH-treatment (week 0) and weekly during treatment. Severities of ARs were
calculated as the sum of problem scores on the 17-item BSSERS-C. Significant changes in sin-
gle items were also explored (e.g., reduced appetite; 1 item, range 0–9).
Dosing of IR-MPH. The IR-MPH doses were individually titrated, based on the weekly
evaluations of symptom reductions and ARs (and the body weight of a child), which were car-
ried out by the clinical investigator. The dose of IR-MPH (mg/kg/day) at the end of the study
was registered.
Physical assessments. The body weight, height, heart rate and blood pressure were mea-
sured every fourth week with the same equipment each time. The study followed the European
guidelines [72] and measured blood pressure after 10 minutes of rest with a sphygmomanome-
ter (nonelectrical) three times and the average of the last two measures was used.
Nonresponder. A combined measure of nonresponder status was defined as patients who
discontinued IR-MPH treatment due to ARs or serious adverse reactions (SARs) or patients
who did not attain Nor/Bnor status, based on the clinical experience that these two types of
poor outcome are interrelated.
Predictors
We explored whether the following clinical baseline characteristics were predictors for
outcomes:
Age (7–9 or 10–12 years), sex, comorbidity (two/more or none/one comorbid psychiatric
diagnosis), intelligence level (IQ 70–85 (inferioritas intellectualis) or IQ > 85), conduct disor-
der (ICD10 DF90.1/DF91.X/DF92.X or no conduct disorder), CGI-S in week 0 as a continuous
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variable [range 1–7] or dichotomized to normal not ill to markedly severity of psychiatric dis-
ease (CGI-S 1–5) and severe to extreme among the most ill patients (CGI-S 6–7), ADHD diag-
nosis (ICD10 DF90.0/ DF90.8/DF90.9 or DF90.1 or DF98.8), and weight in week 0 (� 30kg
or> 30kg).
The primary outcomes measures were: (a) the number of patients (percentage) who
obtained Nor (t-score� 60) or Bnor (� 60 t-score� 70) of the ADHD-RS-C scores of Inatten-
tion and of Hyperactivity-Impulsivity at week 12; (b) the course of the weekly ADHD-RS-C
scores of Inattention and of Hyperactivity-Impulsivity during week 0–12; (c) the course of the
weekly BSSERS-C scores of ARs during week 0–12; and (d) the end-dose IR-MPH.
Statistical analyses
The study was powered to detect effects of genetic variants on outcome regarding the end-
dose of IR-MPH = 1 mg/kg/day (SD 0.5 mg/kg/day) and the average MPH titration dura-
tion = 6 weeks (SD 2 weeks). Setting a significance level of 0.05 (one-sided for genetic variants)
and a power of 0.80, then a minimum relevant effect measured as a regression-coefficient of β
= 0.25 (mg/kg/day) or β = 0.1 (weeks) would be detectable in 94 children with a frequency of
0.20 of the CES1 variant of interest. It was decided to include at least 200 children to be able to
study less frequent variants with a relatively large impact on the outcome [73].
Comparisons of baseline characteristics of included and excluded patients were carried out
with the independent t-test for continuous variables and Chi square test for categorical variables.
Changes from week 0 to week 12 in scores on ADHD-RS-C subscales, ADHD-RS-P sub-
scales, ADHD-RS-T subscales, WFIRS-P subscales, the BSSERS-C sum score, height, weight
and blood pressure were analysed with paired t-test for continuous variables and X2 test for
categorical variables. Missing data on any items were not allowed on ADHD-RS-C,
ADHD-RS-P, ADHD-RS-T and BSSERS-C. Ten percent missing data on items on WFIRS-P
subscales were allowed and missing data on items were set as 0 (never or not at all). Changes in
z-scores and raw scores of response time, variability of response time, omission errors, and
commission errors of TOVA were tested with paired t-test.
To explore the predictive value of clinical baseline characteristics on the responses of 12
weeks of treatment with IR-MPH, linear mixed effect models for repeated measures were used.
Unstructured covariance type fitted the data best as judged by the Akaike information crite-
rion (compound symmetry covariance was used in case a model with unstructured covariance
was impossible to fit). The outcome variables of the mixed models were the sum scores of Inat-
tention and Hyperactivity-Impulsivity (ADHD-RS-C) and the sum score of ARs (BSSERS-C).
The mixed models of Inattention and Hyperactivity-Impulsivity (ADHD-RS-C) tested the
potential impact of explanatory variables of age, sex, intelligence level, conduct disorder,
comorbidity, and time. A mixed model of ARs (BSSERS-C) tested the impact of age, sex, intel-
ligence level, conduct disorder, comorbidity, time, ADHD diagnosis, and CGI-S in week 0.
Time was measured as a continuous variable coded 0, 1, 2. . .12 weeks, and all other explana-
tory variables were measured as categorical variables. It was problematic to estimate the full
mixed models including all explanatory variables simultaneously. Therefore, the explanatory
variables were first tested pairwise (as main factors and interactions) and only significant main
factors and interactions were included in the final multiple mixed model analyses.
Repeated measures of reduced appetite (single item of BSSERS-C) were not normally dis-
tributed. Reduced appetite was dichotomised into mildly reduced or no reduced appetite
(BSSERS-C single score� 3) and moderately to severely reduced appetite (BSSERS-C single
score� 4). To identify potential predictors of reduced appetite over 12 weeks, generalized esti-
mation equations (GEEs) were used. The correlation structure for the model was unstructured
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or M-independent. It was problematic to estimate the full GEEs including all explanatory vari-
ables simultaneously. Therefore, as described above, variables were first tested pairwise, and
only significant main factors and interactions were included in the final multiple GEE analyses.
GEEs of reduced appetite tested the impact of age, sex, intelligence level, conduct disorder,
comorbidity, time, ADHD diagnosis, and CGI-S in week 0. The ADHD disorders were catego-
rised into ICD-10 hyperkinetic disorder or hyperkinetic conduct disorder (DF90.0, DF90.8,
DF90.9, and DF90.1) versus attention deficit disorder without hyperactivity (DF98.8). CGI-S
in week 0 was dichotomised to not ill to markedly severity of psychiatric disease (CGI-S 1–5)
and severe to extreme among the most ill patients (CGI-S 6–7).
To determine independent predictors for the chance of normalisation or borderline nor-
malisation on ADHD-RS-C Inattention and Hyperactivity-Impulsivity, Cox regression analy-
sis with backward elimination was used. The explanatory variables in the Cox regression
model were age, sex, cognitive deficits, conduct disorder, and comorbidity (categorical vari-
ables). Dropouts were censored out when patients exited the study.
The association between the end-dose of IR-MPH per day at week 12 and the severity of the
psychiatric disorder (CGI-S week 0) was explored using linear regression with backward elimi-
nations, with adjustment for sex, age, and weight (week 0).
The IBM SPSS1 version 22 was used for the statistical analyses [74].
Ethics
The study was registered in ClinicalTrials.gov (NCT04366609). The study was approved by the
Danish Data Protection Agency (P-2019-851). The Local Committee on Health Research Eth-
ics was consulted (J.nr. H-B-2009-026) in accordance with national guidelines and the Decla-
ration of Helsinki and the study was evaluated not be within their jurisdiction due study
design as an observational study. Participation was voluntary and data was kept confidential.
The participants could withdraw their consent at any time without having to give reasons and
with no consequences for their further treatment options.
Results
Baseline characteristics of included and excluded patients
Among the 542 patients screened for eligibility (Fig 1), a total of 207 patients (mean age 9.6 SD
1.5), 156 boys (75.4%)) were included in the study (Table 1). Among those with a verified
ADHD diagnosis (n = 418), a total of 211 patients were excluded. The main reason for exclu-
sion were that the parents did not consent to MPH treatment of their children (n = 95, 45.0%),
a delayed decision to initiate MPH treatment, or no clinical indication for MPH treatment as
judged by the clinician. Of the included patients, 187 (90.3%) patients (mean age 9.6 (SD 1.5),
140 boys (74.9%)) completed the 12 weeks study. There were relatively more males (n = 177,
83.9%) among the excluded patients than included in the study (p = 0.030) (Table 1).
The comparison of included versus excluded patients furthermore showed that the included
patients had significantly higher ADHD-RS-P scores, and at the same time, significantly lower
ADHD-RS-T scores compared with those excluded (S3 Table). There were no other significant
differences in ADHD symptoms between included and excluded patients or between the
included patients and the subgroup of patients excluded solely because their parents refused
medicine (n = 95). This group of patients who were excluded solely because of their parents’
refusals were characterized by lower ADHD-RS-P scores compared to patients excluded due
to other reasons (n = 116), 10.9 (SD 5.3), and 13.9 (SD 6.3), respectively, (p< 0.001) (for fur-
ther baseline characteristics see S4 Table). Only five children were excluded because of parents’
refusals to let them participate in the study.
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The treatment response during the first 12 weeks after initiation of
IR-MPH treatment
The reasons for discontinuation of IR-MPH treatment. The clinicians decided when to
discontinue medication with IR-MPH due to ARs or SARs (n = 12, 5.8%). Of the patients who
discontinued the treatment with IR-MPH, one experienced onset of psychotic symptoms
Fig 1. TREND, flow diagram of inclusion. ICD-10 = International Classification of Diseases and Related Health
Problems, ADHD = Attention-deficit/hyperactivity disorder, MPH = Methylphenidate, INDICES = INDIvidualised
drug therapy based on pharmacogenetics: focus on carboxylesterase 1, AR = Adverse reaction, SAR = Serious adverse
reaction. 1 = Treatment initiated after the study inclusion period was terminated. 2 = Clinician decision of patient’s
discontinuation of treatment with MPH due to adverse events, ARs, and SARs.
https://doi.org/10.1371/journal.pone.0253727.g001
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(0.5%) and another patient had progression in seizures (0.5%), both were classified as SARs
(1.0%). A total of 10 patients (4.8%) discontinued the treatment because of ARs: three patients
(1.4%) because of irritability, two patients (1.0%) because of hypertension (increase in a sys-
tolic blood pressure and/or diastolic blood pressure to a level corresponding to the 95–99 per-
centile for age and gender), two patients (1.0%) because of tics, one patient (0.5%) because of
sadness, one patient (0.5%) because of hyperactivity, and one patient (0.5%) because of urticar-
ial reaction. Six of these 12 patients had ARs or SARs that were detected by the weekly moni-
toring with BSSERS-C, whereas the remaining ARs were reported spontaneously.
One other patient (0.5%) reported psychotic symptoms during treatment, and a thorough
clinical evaluation established that intermittent psychotic symptoms had been present for sev-
eral years before initiation of MPH treatment. The medication was discontinued, and the
relapse of psychotic symptoms was classified as an adverse event. Furthermore, six patients
(2.9%) were non-compliant/non-adherent and discontinued their treatment and one patient
(0.5%) due to no symptom reduction.






medicine1 (n = 95)
Boys, n (%) 156 (75.4) 177 (83.9) 75 (78.9)
Age, years, mean (SD) 9.6 (1.5) 9,9 (1.5) 9.6 (1.6)
Age, 7–9 years, n (%) 133 (64.3) 119 (56.4) 56 (58.9)
Age, 10–12 years, n (%) 74 (35.7) 92 (43.6) 39 (41.1)
ADHD diagnoses (ICD-10)
Disturbance of activity and attention, hyperkinetic disorder other, hyperkinetic disorder unspecified. (F
90.0, F 90.8, F 90.9) n (%)
172 (83.1) 163 (77.3) 74 (77.9)
Hyperkinetic conduct disorder (F 90.1) n (%) 12 (5.8) 14 (6.6) 5 (5.3)
Attention deficit disorder without hyperactivity (F 98.8,) n (%) 23 (11.1) 34 (16.1) 16 (16.8)
Comorbidity (ICD-10)
Tic disorders. (F95.X) n (%) 17 (8.2) 14 (6.6) 4 (4.2)
Externalizing disorders. Conduct disorders, mixed disorders of conduct and emotions (F 91.X, F 92.
X) n (%)
14 (6.8) 9 (4.3) 4 (4.2)
Specific developmental disorders. (F81.X-83.X, F88.X) n (%) 46 (22.2) 46 (21.8) 26 (27.4)
Cognitive deficits. Inferioritas intellectualis, mental retardation (R41.82, F70-79) n (%) 56 (27.1) 62 (29.4) 27 (28.4)
Encopresis and/or enuresis. (F98.0–98.1) n (%) 24 (11.6) 18 (8.5) 8 (8.4)
Autism spectrum disorders. (F84.X) n (%) 26 (12.6) 40 (19.0) 15 (15.9)
Attachment disorders. (F94.X) n (%) 3 (1.4) 7 (3.3) 1 (1.1)
Emotional disorders. Depressive episode, persistent mood-, obsessive-compulsive-, reaction to severe
stress, and adjustment disorders, emotional disorders with onset specific to childhood. (F 32.X, F 34.X,
F 42.X, F 43.X, F 93.X) n (%)
27 (13.0) 23 (10.9) 10 (10.5)
Number of comorbid psychiatric diagnoses
No comorbidity, n (%) 72 (34.8) 64 (30.3) 29 (30.5)
1 comorbid diagnosis, n (%) 78 (37.7) 85 (40.3) 39 (41.1)
2 comorbid diagnoses, n (%) 39 (18.8) 52 (24.6) 25 (26.3)
3 comorbid diagnoses, n (%) 15 (7.2) 10 (4.7) 2 (2.1)
4 comorbid diagnoses, n (%) 3 (1.4) 0 (0.0) 0 (0.0)
ICD-10 = International Classification of Diseases and Related Health Problems, ADHD = Attention-deficit/hyperactivity disorder.
1 Patients, who refused medicine, were a subgroup of excluded patients.
2 R41.8 referred to diagnose from the diagnostic conference and/or from the intelligence test (WISC) (IQ = 70–85) depending on data access.
https://doi.org/10.1371/journal.pone.0253727.t001
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ADHD core symptoms, conduct problems, daily and social functioning. A total of 137
(73.2%) patients obtained Nor/Bnor (70 (37.4%) patients obtained Nor) on the Inattention
subscale (ADHD-RS-C) at week 12 (Nor and Bnor are separated in S5 Table). Of these
patients, 111 (81.0%) were boys and 89 (65.0%) were 7 to 9 years of age. A total of 157 (84.0%)
patients obtained Nor/Bnor (95 (58,8% patients obtained Nor) on the Hyperactivity-Impulsiv-
ity subscale (ADHD-RS-C) at week 12. Of these patients, 115 (55.6%) were boys and 103
(65.6%) were 7 to 9 years of age. In summary, 19 (10.1%) patients were not Nor/Bnor on any
of the subscales at week 12, 126 (67.4%) patients were Nor/Bnor on both subscales of
ADHD-RS-C at week 12, and 42 (22.5%) patients were Nor/Bnor on either the Inattention or
the Hyperactivity-Impulsivity subscale of ADHD-RS-C at week 12.
Changes in sum scores from week 0 to week 12 showed a mean significant reduction and
an effect size between 0.3 to 2.7 of severity of inattention symptoms and hyperactivity-impul-
sivity symptoms rated by clinicians, parents, and teachers (ADHD-RS-C, ADHD-RS-P, and
ADHD-RS-T, Table 2). Reduction of conduct problems was statistically significant in parents’
ratings (p< 0.001) but not in teachers’ ratings (p = 0.293).
The mean percent reductions of scores on the clinician-rated ADHD-RS-C subscale from
week 0 to 12 were 52.0% on Inattention and 56.0% on Hyperactivity-Impulsivity, and the
mean percentage reductions on the parent-rated ADHD-RS-P subscales were 48.1% on Inat-
tention, 45.0% on Hyperactivity-Impulsivity, and 50.7% on Conduct problems (S6 Table).
Patients significantly improved on the CGI-S scale from week 0 to week 12. A total of 67
(35.8%) patients were rated with a score of 1 or 2 (normal to mildly ill) on CGI-S after 12
weeks of treatment (p< 0.001, the mean difference between week 0 and 12 was 0.4 (SD 0.5,
95%CI 0.3 to 0.4). The mean score on CGI-S was 5.3 (SD 1.0) in week 0 and 3.0 (SD 1.1) after
12 weeks of treatment (p< 0.001, M difference 2.3, SD 1.0, 95%CI 2.2 to 2.5). A total of 171
patients (91.5%) had a score of 1 or 2 (very much or much improved) on CGI-I after 12 weeks
of treatments. The mean score on CGI-I at week 12 was 1.8 (SD 0.6) (Table 2).
After 12 weeks of treatment, the patients’ daily and social functioning were improved on
WFIRS-P, which showed a significant reduction of symptoms of all six subscales from week 0
to week 12 (S7 Table). Mean subscale index scores of WFIRS-P at week 0 and 12 were�1,
meaning that the overall level of functioning was mildly affected in each domain (range of
index score 0–3). The largest mean reductions on the WFIRS-P were on the school subscale
and the social life subscale with mean reductions of 0.4 (SD 0.4) and 0.4 (SD 0.5), respectively,
and the smallest mean reductions on the subscales were on the daily life subscale and the risk
behaviour subscale with mean reductions of 0.1 (SD 0.4) and 0.1 (SD 0.2). All reductions were
statistically significant and had effect sizes between 0.2 to 1.6.
The four mean TOVA outcomes showed significant improvements and effect sizes between
0.6 to 1.1 in response time, variability of response time, omission errors, and commission
errors (n = 115) from week 0 to week 12. Compared to week 0, at week 12 there were improve-
ments in standard deviations of 1.0 on response time, 1.4 on variability of response time, 0.9
on omission errors, and 0.7 on commission errors (S7 Table). The mean time from midday
IR-MPH dose to TOVA test was 108 minutes (range 9 to 193), and the mean midday dose was
0.42 mg IR-MPH per kg (SD 0.13) (n = 106) at week 12.
Attrition during the study. There were no differences between the patients who com-
pleted the study (n = 187) and those who discontinued IR-MPH treatment due to ARs (n = 12)
at entry (week 0) in mean sum scores of Inattention and Hyperactivity-Impulsivity
(ADHD-RS-C) (19.9 (SD 3.7) and 18.0 (SD 5.8) vs. 20.3 (SD 3.2) and 19.7 (SD 5.2), p = 0.742
and p = 0.315) and in mean sum score of ARs (BSSERS-C) (17.6 (SD 10.8) vs. 17.9 (SD 7.8),
p = 0.928).
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Adverse reactions. Overall the mean sum problem score of the BSSERS-C rating scale sig-
nificantly declined over 12 weeks of treatment (pre-post mean difference 2.8 (SD 8.6),
p< 0.001) (Table 2, single-item ARs of BSSERS-C in S8 Table). Reduced appetite was the only
BSSERS-C-rated AR problem score that increased significantly over time, whereas the other
BSSERS-C-rated AR problem scores were either stable or decreased over time (e.g., the largest
decrease on any single AR problem score was found for euphoria with a mean decrease of 0.7
(SD 1.4) p< 0.001, 95%CI 0.5 to 0.9). There was no significant increase in mean blood pres-
sure, and no change in heart rate from week 0 to week 12. There was a significant increase in
children’s height with a mean of 1.2 cm (SD 1.1) despite a mean loss of weight of 0.9 kg (SD
1.5) (Table 2).
Table 2. Clinical follow-up from week 0 to week 12 (n = 187).
ADHD rating scales Week 0 M (SD), n (%) Week 12 M (SD), n (%) Week 0 versus week 12 Cohen’s d
M dif. (SD) 95% CI t (df) p-value
Parent
Inattention 17.41 (5.0) 9.21 (4.2) 8.2 (5.1) (7.5, 9.0) 21.3 (173) < 0.001 1.8
Hyperactivity-Impulsivity 15.62 (6.0) 8.62 (4.7) 7.0 (5.7) (6.2, 7.9) 16.2 (170) < 0.001 1.2
Inattention and Hyperactivity-Impulsivity 33.23 (9.4) 17.73 (7.9) 15.5 (9.4) (14.1, 17.0) 21.1 (162) < 0.001 1.6
Conduct problems 10.74 (5.9) 5.34 (4.1) 5.4 (5.1) (4.7, 6.2) 14.2 (178) < 0.001 1.1
Teacher
Inattention 16.95 (4.7) 11.25 (5.1) 5.6 (5.1) (4.7, 6.5) 12.4 (126) 0.001 1.1
Hyperactivity-Impulsivity 9.16 (5.7) 7.76 (4.9) 1.4 (5.2) (0.5, 2.3) 3.0 (124) 0.004 0.3
Inattention and Hyperactivity-Impulsivity 25.97 (9.0) 18.67 (8.4) 7.2 (8.9) (5.6, 8.9) 8.8 (117) < 0.001 0.8
Conduct problems 4.88 (4.7) 4.48 (4.1) 0.4 (4.4) (-0.4, 1.2) 1.1 (127) 0.293 0.1
Clinician
Inattention 19.9 (3.7) 9.6 (3.7) 10.3 (4.0) (9.7, 10.9) 35.2 (186) < 0.001 2.6
Hyperactivity-Impulsivity 18.0 (5.8) 7.9 (4.0) 10.1 (5.1) (9.4, 10.8) 27.3 (186) < 0.001 2.0
Inattention and Hyperactivity-Impulsivity 37.9 (7.8) 17.5 (6.8) 20.4 (7.7) (19.3, 21.5) 36.5 (186) < 0.001 2.7
CGI-S 5.3 (1.0) 3.0 (1.1) 2.3 (1.0) (2.2, 2.5) 31.5 (186) < 0.001 2.2
CGI-S� 2 0 (0.0%) n = 67 (35.8%) 0.4 (0.5) (0.3, 0.4) 10.2 (186) < 0.001
CGI-I - 1.8 (0.6) - - - -
CGI-I� 2 - n = 171 (91.5%) - - - -
Weight, kg 36.39 (11.0) 35.49 (11.1) 0.9 (1.5) (0.7, 1.15) 8.3 (183) < 0.001 0.6
Height, cm 140.19 (10.8) 141.39 (10.7) -1.2 (1.1) (-1.4, -1.0) -14.8 (183) < 0.001 1.1
Diastolic blood pressure, mmHg 67.110 (7.1) 66.410 (7.4) 0.7 (9.4) (-0.7, 2.0) 0.9 (182) 0.344 0.1
Systolic blood pressure, mmHg 102.210 (8.9) 101.810 (9.7) 0.3 (9.9) (-1.2, 1.7) 0.4 (182) 0.693 0.0
Heart rate, bpm 79.211 (10.9) 78.211 (11.9) 1.0 (15.1) (-1.2, 3.3) 0.9 (180) 0.341 0.1
BSSERS-C 17.39 (10.5) 14.59 (9.0) 2.8 (8.6) (1.5, -4.0) 4.4 (183) < 0.001 0.6
Reduced appetite 0.712 (1.3) 1.912 (1.5) -1.2 (1.8) (-1.5, 1.0) -9.2 (185) < 0.001 0.7
Methylphenidate mg/kg/day 0.3 (0.1) (initial dose) 1.0 (0.3) -0.7 (0.3) (-0.7, -0.7) -34.2 (186) < 0.001 2.4
Paired t-test between outcomes of week 0 and week 12. M = mean, M dif. = Mean difference, SD dif. = Standard deviation difference, n = number. Number of
participants with observed outcome data: 1 n = 174, 2 n = 171, 3 n = 163, 4 n = 179, 5 n = 127, 6 n = 125, 7 n = 118, 8 n = 128, 9 n = 184, 10 n = 183, n 11 = 181, 12 n = 186.
ADHD-Rating Scale (ADHD-RS, DuPaul). Inattention subscale: 9 items, [range 0–27]. Hyperactivity-Impulsivity subscale: 9 items [range 0–27]. Conduct problems
subscale: 8 items, [range 0–24]. Rated by clinician, parent, or teacher.
Clinical Global Impression Severity (CGI-S): 1 item, [range 1–7]. CGI-S, 1 = Not ill at all. CGI-S, 2 = Borderline ill.
Clinical Global Impression Improvement (CGI-I): 1 item, [range 1–7]. CGI-I, 1 = Very much improved. CGI-I, 2 = Much improved.
Barkley’s Stimulant Side Effects Rating Scale, clinician rated (BSSERS-C). Whole scale: 17 items, [range 0–153]. Reduced appetite: single item, [range 0–9].
https://doi.org/10.1371/journal.pone.0253727.t002
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Nonresponders. Thirty-one patients (15.0%) were nonresponders; of these, 12 (5.8%)
patients discontinued IR-MPH treatment because of ARs/SARs, and 19 patients (9.1%) were
not Nor/Bnor on any of the ADHD-RS-C subscales. Responders (n = 168) and nonresponders
did not differ with respect to age, sex, and comorbidity (S9 Table). Nonresponders were char-
acterised by having more severe ADHD and global symptoms than responders at week 0
(mean sum scores of Hyperactivity-Impulsivity were 21.5 (SD 4.4) vs. 17.5 (SD 5.7), p� 0.001,
and mean CGI-S scores were 5.9 (SD 0.8) vs. 5.2 (SD 0.9), p� 0.001), and a higher mean score
of problems on BSSERS-C (21.3 (SD 11.3) vs. 17.0 (SD 10.4), p = 0.034) at week 0.
Modelling the response and the predictors of response during the first 12
weeks of treatment
Course of inattention. Among the investigated clinical characteristics, sex, age, and time
(number of weeks in treatment) were significantly associated with the course of inattention
symptoms, rated on the Inattention subscale (ADHD-RS-C, range 0–27), when analysed in the
linear mixed effect model (Table 3, graphs of Inattention Fig 2A). The estimated effects of time
corresponded to a mean reduction of 0.8 of the Inattention sum score per week in subgroups
of sex and age throughout the treatment period. Girls aged 7 to 9 years had a lower estimated
mean score of Inattention symptoms in week 0 (score 17.5) than the group of girls aged 10 to
12 years (score 18.6) in week 0. Boys aged 7 to 9 years had a higher estimated mean score of
Inattention symptoms in week 0 (score 19.4) than boys aged 10 to 12 years (score 18.2) in
week 0. None of the investigated variables (age, sex, intelligence level, conduct disorder, and
comorbidity) had a significant interaction with time, and the differences in estimated mean
scores in week 12 between sex and age were the same as in week 0.
Course of hyperactivity-impulsivity. In the linear mixed effect model for repeated mea-
sures, only age and time (number of weeks in treatment) were significantly associated with the
course of hyperactivity-impulsivity symptoms, rated on the Hyperactivity-Impulsivity subscale
(ADHD-RS-C, range 0–27) (Table 3, graphs of Hyperactivity-Impulsivity Fig 2B). Patients
aged 7 to 9 years had an estimated baseline score of 16.0 and an estimated decrease in symp-
toms of 0.8 per week. Patients aged 10 to 12 years had an estimated baseline score of 13.3 and
estimated decrease in symptoms of 0.6 per week. In week 12, patients aged 7 to 9 years had a
score of 6.8 and patients aged 10 to 12 years had an estimated score of 6.3 (i.e., the scores from
the two age groups of patients ended up at about the same level).
Normalisation or borderline normalisation of the clinician-rated ADHD core symp-
toms. Female sex (HR = 0.64, 95% CI 0.54 to 0.75) and a diagnosis of inferioritas intellectualis
(HR = 0.74, 95%CI 0.63 to 0.86) were significant predictors of a lower chance of Nor/Bnor on
the Inattention subscale (ADHD-RS-C) (Table 4).
Young age (7–9 years) (HR = 0.88, 95%CI 0.71 to 0.96) and inferioritas intellectualis
(HR = 0.82, 95%CI 0.78 to 0.99) significantly predicted lower chance of Nor/Bnor on the
Hyperactivity-Impulsivity subscale (ADHD-RS-C). Comorbidity (HR 1.17, 95%CI 1.02 to
1.35) significantly improved the chance of Nor/Bnor on the Hyperactivity-Impulsivity subscale
(ADHD-RS-C) (Table 4). Post hoc analysis did not show any significant differences in sum
scores of Inattention or Hyperactivity-Impulsivity subscale (ADHD-RS-C) in week 0 between
patients with none or one psychiatric comorbid diagnosis and those with two or more psychi-
atric comorbid diagnoses.
Adverse reactions. The mean reduction in the BSSERS-C problem score was 0.3 per
week. Among the investigated clinical characteristics, only CGI-S measured in week 0 and
time (number of weeks in treatment) were significantly associated with the course of ARs in
the linear mixed effect model for repeated measures (BSSERS-C, range 0–153) (Table 3, graphs
PLOS ONE Treatment outcomes of a 12-week naturalistic study of children with ADHD
PLOS ONE | https://doi.org/10.1371/journal.pone.0253727 October 21, 2021 14 / 29
Table 3. Baseline characteristics as predictors for symptom reductions and adverse reactions (n = 207).
Linear mixed model
Inattention Estimate 95% CI p-value
Intercept 18.21 (17.37, 19.05) < 0.001
Week - - < 0.001
Week -0.77 (-0.81, -0.72) < 0.001
Age - - 0.062
10–12 years (ref.) - - -
7–9 years 0.38 (-0.66, 1.30) 0.521
Sex - - 0.794
Boys (ref.) - - -
Girls 1.38 (-0.19, 2.94) 0.084
Age�Sex - - 0.013
Boys�10–12 years - - -
Boys�7–9 years - - -
Girls�10–12 years - - -
Girls�7–9 years -2.50 (-4.46, -0.54) 0.013
Hyperactivity-Impulsivity Estimate 95% CI p-value
Intercept 13.30 (12.13, 14.47) < 0.001
Week - - < 0.001
Week -0.58 (-0.66, -0.50) < 0.001
Age - - < 0.001
10–12 years (ref.) - - -
7–9 years 2.65 (1.19, 4.11) < 0.001
Week�age - - < 0.001
Week�10–12 years (ref.) - - -
Week�7–9 years -0.18 (-0.28, -0.08) < 0.001
Adverse reactions Estimate 95% CI p-value
Intercept 21.66 (19.84, 23.49) < 0.001
Week - - < 0.001
Week -0.28 (-0.37, -0.19) < 0.001
CGI-S, week 0 - - < 0.001
CGI-S, 6–7 (ref.) - - -
CGI-S, 5 -4.53 (-7.00, -2.06) < 0.001
CGI-S, 4 -4.30 (-7.77, -0.84) 0.015
CGI-S, 1–3 -8.25 (-14.15, -2.35) 0.006
General Estimating Equation
Reduced appetite Estimate 95% CI p-value OR 95% CI
Intercept 1.90 (1.44, 2.37) < 0.001 6.71 (4.21, 10.71)
Week - - < 0.001
Week -0.04 (-0.08, 0.00) 0.069 0.96 (0.93, 1,00)
CGI-S, week 0 - - < 0.001
CGI-S 6–7 (ref.) - - -
CGI-S 1–5 0.88 (0.35, 1.41) < 0.001 2.41 (1,42, 4,08)
Linear mixed model for repeated measures of sum scores of Inattention, Hyperactivity-Impulsivity, and adverse reactions. ADHD-Rating Scale, clinician rated.
(ADHD-RS-C, DuPaul). Inattention: 9 items, [range 0–27]. Hyperactivity-Impulsivity: 9 items, [range 0–27]. Barkley’s Stimulant Side Effects Rating Scale, clinician
rated (BSSERS-C). Whole scale: 17 items, [range 0–153]. Only significant values (p< 0.05) of the explanatory variables as main factors and/or interactions are listed in
the table. Explanatory variables; continuous variable: time (defined as 13 weeks from week 0 to 12) and categorical variables: sex, age, Clinical Global Impression
Severity (CGI-S) in week 0. CGI-S, [range 1–7], divided into four groups: CGI-S 1–3 = not ill at all, borderline ill, mildly ill, CGI-S 4 = moderately ill, CGI-S 5 = markedly
ill, CGI-S 6–7 = severely ill, among the most extreme ill.
General Estimating Equation for repeated measures of reduced appetite. BSSERS-C, single item, reduced appetite, [range 0–9]. No or mild reduced appetite 0–3,
moderate to server reduced appetite 4–9. Only significant values (p< 0.05) of the explanatory variables as main factors and/or interactions are listed in the table.
Explanatory variables; continuous variable: time (defined as 13 weeks from week 0 to 12) and categorical variables: CGI-S in week 0 divided into CGI-S 1–5 and CGI-S
6–7.
Estimate refers to the sum score of the scale (ADHD-RS-C or BSSERS-RS).
https://doi.org/10.1371/journal.pone.0253727.t003
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of ARs Fig 2C). Patients rated severely ill and most extremely ill (CGI-S 6–7) in week 0 had a
more severe BSSERS-C problem score (mean score 21.7) before initiation of treatment than
patients with a lower-rated CGI-S score in week 0. Patients who were rated moderately ill
(CGI-S 5) at baseline had an estimated mean BSSERS-C problem score of 17.2, patients rated
markedly ill on CGI-S (CGI-S 4) had an estimated mean BSSERS-C problem score of 17.4, and
patients rated not ill at all, borderline ill, or mildly ill (CGI-S 1–3) had an estimated mean
BSSERS-C problem score of 13.4 before initiation of treatment. None of the investigated vari-
ables (age, sex, intelligence level, conduct disorder, comorbidity, time, ADHD diagnosis, and
CGI-S in week 0) had a significant interaction with time.
Reduced appetite. Of the investigated AR items on BSSERS-C, reduced appetite was the
only item that significantly increased in problem score over the 12-week treatment period.
Reduced appetite was post hoc defined as a problem score of 4–9 on BSSERS-C. Among the
investigated clinical characteristics in week 0, only CGI-S was significantly associated with the
course of reduced appetite in the model of GEE for repeated measures (BSSERS-C, single item,
0–3 = no reduced appetite, 4–9 = reduced appetite) (Table 3). Severely ill and most extremely ill
rated patients (CGI-S 6–7) had a significantly higher risk of reduced appetite compared with
patients rated not ill to moderately ill (CGI-S 1–5) in week 0 and throughout the whole treat-
ment period (OR = 2.41, 95%CI 1.42 to 4.08). The probability of reduced appetite in week 0
was 13.0% for patients rated severely ill and most extremely ill and 5.8% for patients not ill to
Fig 2. Examples of graphs for estimations sum scores of inattention, hyperactivity-impulsivity, and adverse reactions throughout the 12 weeks as
estimated by the linear mixed models, n = 207. Clinician rated ADHD-Rating-Scale (ADHD-RS-C); Inattention subscale, 9 items [range 0–27] and
Hyperactivity-Impulsivity subscale, 9 items [range 0–27]. Clinician rated Barkley’s Stimulant Side Effect Rating Scale (BSSERS-C), 17 items, [range
0–153]. Explanatory variables: Sex, age (7 to 9 years and 10 to 12 years), functional impairments in week 0, and Clinical Global Impression Severity
(CGI-S). CGI-S devided into: 1–3 = Not ill, borderline ill, mildly ill. CGI-S 4 = Moderately ill, CGI-S 5 = Markedly ill. CGI-S 6–7 = Severly ill, among the
most extreme ill patients.
https://doi.org/10.1371/journal.pone.0253727.g002
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moderately ill. The proportion of patients with reduced appetite did not change significantly
over time (weeks, p = 0.069).
Baseline characteristics as predictors for end-dose of IR-MPH. The mean end-dose of
IR-MPH was 1.0 mg/kg/day (SD 0.3, Table 2). Higher CGI-S scores at week 0 predicted a
higher end-dose of IR-MPH. CGI-S at week 0 and age explained together 12.7% (p< 0.001) of
the variance of the end-dose IR-MPH. The estimated effect of being “among the most
extremely ill patients” in week 0 (CGI-S 7) corresponded to an end-dose of IR-MPH 1.19 mg/
kg/day, whereas being rated “mildly ill” in week 0 (CGI-S 3) corresponded to an end-dose of
IR-MPH 0.85 mg/kg/day (Table 5). Young age predicted a lower end-dose of IR-MPH.
Patients aged 7 to 9 years were estimated to receive a 0.13 mg/kg/day lower end-dose of
IR-MPH than patients aged 10–12 years.
Discussion
This study is a prospective, uncontrolled, ecologically valid study aimed at exploring the course
and outcome of a group of patients treated with IR-MPH treatment in a routine child and ado-
lescent clinic in a real-world setting [29]. This heterogeneous group of patients with substantial
psychiatric comorbidity, including autism spectrum disorders and inferioritas intellectualis,
were offered an individually titrated optimal dosing of IR-MPH based on weekly assessments
Table 4. Baseline characteristics as predictors for the chance of normalisation or borderline normalisation of the
clinician rated ADHD core symptoms score (n = 207).
Predictors for the chance of normalisation or borderline normalisation of ADHD symptoms
Inattention HR 95% CI p-value
Sex (girls) 0.64 (0.54, 0.75) < 0.001
Inferioritas intellectuals 0.74 (0.63, 0.86) < 0.001
Hyperactivity-Impulsivity HR 95% CI p-value
Age (7–9 years) 0.88 (0.71, 0.96) 0.031
Inferioritas intellectuals 0.82 (0.78, 0.99) 0.011
Comorbidity 1.17 (1.02, 1.35) 0.030
Cox regressions of time to first normalisation (zero standard deviation) or borderline normalisation (one standard
deviation) of ADHD core symptoms due to Danish norms of sex and age on ADHD-Rating Scale, clinician rated
(ADHD-RS-C, DuPaul). Inattention subscale: 9 items, range 0–27. Hyperactivity-Impulsivity subscale: 9 items, range
0–27. Only last model of cox regression with backward elimination are listed in the table. HR = Hazard ratio.
Independent predictors: Sex, age, comorbidity (� 2 comorbid diagnosis), and intelligence level (inferioritas
intellectuals, ICD10-R41.8) from the diagnostic conference and/or from the intelligence test (WISC) (IQ = 70–85)
depending on data access).
https://doi.org/10.1371/journal.pone.0253727.t004
Table 5. Baseline characteristics as predictors for end-dose of IR-MPH (n = 187).
Predictors for end-dose of IR-MPH dose/mg/kg/day
b std Error Beta t p-value 95% CI of estimate
Constant 0.56 0.12 4.84 < 0.001 (0.33, 0.79)
CGI-S, week 0 0.09 0.02 0.29 4.32 < 0.001 (0.05, 0.13)
Age (7–9 years) -0.13 0.04 -0.16 -3.05 0.003 (-0.21, -0.05)
Linear regression for end-dose of Immediate Release Methylphenidate (IR-MPH).
Explaining variables are measured in week 0. Clinical Global Impression Severity (CGI-S) in week 0, [range 1–7].
Model Summary: R = 0.37, R Square = 0.14, Adjusted R Square = 0.13, Std. Error of the Estimate = 0.27.
https://doi.org/10.1371/journal.pone.0253727.t005
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of ADHD core symptoms and ARs. Children with ADHD displayed statistically and clinically
significant improvements of these core symptoms across informants, global level of symptoms,
and parent-reported impairments of daily life functioning. The clinical findings were sup-
ported by an objective performance based measure of the patients’ sustained attention by
TOVA, which also showed significant improvements after 12 weeks of treatment with
IR-MPH. Altogether, 15% were classified as nonresponders, and compared with the respond-
ers, they were characterised by more severe symptoms of hyperactivity-impulsivity and global
impairment before initiation of treatment. Interestingly, the mental and physical complaint,
measured as potential ARs, scored highest before initiation of treatment and dropped signifi-
cantly during the up-titration of IR-MPH, suggesting that the complaints reflected general
health and mental health problems which were related to the ADHD illness rather than ARs to
IR-MPH treatment. However, two types of well-known ARs to IR-MPH (reduced appetite and
weight loss) increased during the period of IR-MPH treatment. To our knowledge this is the
first naturalistic observational study that monitored ARs weekly in a 12-week period.
Results were mixed regarding potential predictors of outcome of the individually titrated
IR-MPH-treatment, suggesting no need to modify the dosing of IR-MPH according to age,
gender, IQ between 70 and 85, or psychiatric comorbidity. Although the chance of Nor/Bnor
was reduced for children with inferioritas intellectualis and increased for children with psychi-
atric comorbidity in the Cox regression analyses, this pattern was not confirmed in the more
powerful mixed models of the course of symptoms.
The individually titrated doses varied (range 0.3–2.0 mg/kg/day), and higher levels of clini-
cal global impairments before initiation of treatment predicted higher end-doses, whereas
being between 7 and 9 years old was associated with slightly lower end-doses. The mean end-
dose of 1.0 mg/kg/day was within the clinical recommendations.
The pattern of higher parent-rated ADHD core symptoms and, at the same time, lower
teacher-rated ADHD core symptoms at entry was seen among included children for whom the
parents accepted IR-MPH-treatment, and the opposite pattern was seen among children
excluded due to parents’ refusals of IR-MPH-treatment. This is a strong reminder that parents’
conceptions of child ADHD core symptoms may impact the clinical decision to offer IR-MPH
treatment of children.
Outcomes of MPH treatment vary in the literature, which may reflect definitions of
response criterions used, the choice of ADHD rating scales, the length of observation period
and the type of informants. Compared to a systematic review of efficacy trials (stimulant medi-
cation) reporting symptom reductions in the range of 10 to 18 in absolute scores [24], this
study found a mean symptom reduction of 20.4 (SD 7.7) on the ADHD-RS-C, suggesting clini-
cal effects within the same range as reported in efficacy trials. Furthermore, the effect sizes
from 0.8 to 2.7 on ADHD core symptoms (a part from the teacher rated hyperactivity-impul-
sivity symptoms with an effect size of 0.3) were comparable to metanalyses with effect sizes
from 0.54 to 1.78) for pre-post change in ADHD core symptoms after initiation of MPH treat-
ment [14, 15], Direct comparisons of the present findings with results from other naturalistic
observational studies with MPH naïve patients are only possible by comparing scores on the
CGI-S and CGI-I (response rates defined as CGI-I� 2 and CGI-S� 2 at end of study). Kim
et al. [32] found a higher CGI-S response rate (46.1%) after 12 weeks of treatment compared to
the response rate in the present study (35.8%). Whereas two other studies found lower CGI-I
response rates; 79.1% after 8 weeks of treatment [41] and 49.9% after 24 weeks of treatment
[35] than the response rate of 91.5% in the present study (S2 Table and Table 2). This could
indicate that, the present study included very ill patients, but the patients still had high
response rates measured with CGI-I after 12 weeks of treatments compared to other studies.
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The present study found a significant improvement of the level of daily and social function-
ing (total mean score of WFIRS-P) though the overall level of functioning in daily life rated by
parents, was only mildly affected at study entry [60].
In line with findings in RCTs [64, 65] and naturalistic observational studies [35, 33], we
found significant improvements of attention on all TOVA parameters. The variability of
response time exhibited the largest improvement, indicating higher stability of attention dur-
ing the whole test period.
Contrary to expectations, problem scores rated by the clinicians as potential ARs
(BSSERS-C) were rated highest before medication and decreased during the treatment period
(see S6 Table for single items), with the exception of appetite (BSSERS-C) that decreased along
with a decrease in weight during treatment. The 17-item rating scale of BSSERS has been vali-
dated in a triple-blind placebo-controlled crossover study (n = 83), in which parents and teach-
ers rated ARs of MPH in children with ADHD [49]. In that study, BSSERS was found useful to
measure reduced appetite, insomnia, headache, and stomachache (rated by parents), and star-
ing, sadness, and anxiety (rated by teachers) during the treatment period, but the same ARs
were also reported at lower levels during the placebo periods.
Many of the AR items rated on BSSERS-C may not be true ARs associated to IR-MPH but
may reflect symptoms of ADHD or psychiatric comorbidity [75]. This may challenge the fre-
quent use of BSSERS as a valid instrument for assessment of ARs associated with stimulant
treatment [15, 33, 34, 39, 48]. Furthermore, only half of the patients who dropped out due to
ARs experienced ARs detected on BSSERS-C in this study. There are few other validated AR
rating scales, such as the Pittsburgh Side-Effects Rating Scale [76] and Subject’s Treatment
Emergent Symptom Scale [77], which are not very frequently used in research. When studies
systematically use the ARs ratings scales, very few ARs increases during treatment with MPH
and even decreases of “ARs” are found (irritability, proneness to cry, anxiety, nail biting, eupho-
ria, and sadness) [75, 78, 79]. But the literature search revealed a general lack of systematic
reporting of ARs, and several studies limited AR assessments to spontaneous reports. Reduced
appetite and insomnia are the most frequent reported ARs in RCTs [15, 80] and in naturalistic
observational studies [33, 34, 39]. The present study had a low discontinuation rate due to ARs
(5.8%). Similar rates are found in other naturalistic observational studies (8.0% in [31] and
4.5% in [33]). Our findings are in line with a recent Cochrane review of non-randomized stud-
ies of children (5–18 years) with ADHD treated with MPH, which identified a discontinua-
tions rate of 1.2% due to SARs and a discontinuations rate of 6.2% due ARs [81]. The
discontinuation rates were low despite of relative high frequencies of reported ARs (insomnia
(17.9%), headache (14.4%), abdominal pain (10.7%), and reduced appetite (6.2%)). In the pres-
ent study, there was no increase in mean blood pressure during IR-MPH-treatment, which is
in line with findings from another naturalistic observational study [36]. However, two of our
patients discontinued treatment due to hypertension. Overall, the patients who completed the
12 weeks of treatment in the present study seemed to report fewer clinically significant ARs
than patients in other naturalistic observational studies [33, 39] (S2 Table).
Children aged 7–9 years had a lower chance of normalisation or borderline normalisation
of hyperactivity-impulsivity symptoms (Nor/Bnor of ADHD-RS-C) after 12 weeks of treat-
ment than children aged 10–12 years, even though, children aged 7–9 years had a higher sum
score of hyperactivity-impulsivity symptoms (ADHD-RS-C) in week 0 and had a higher
weekly reduction of symptoms than children aged 10–12 years. In both cases, the differences
were minor and hence of limited clinical significance. Also, the differential reduction of
ADHD symptoms was explained by symptom severity differences at entry, whereas the end
scores were similar for the two age groups.
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The subgroup of girls aged 7–9 years had a lower sum score of inattention symptoms
(ADHD-RS-C) than girls of age 10–12 years throughout the treatment period, but the weekly
reduction of inattention symptoms was the same regardless of age and gender. The contradict-
ing finding that girls had a lower chance of normalisation or borderline normalisation of inat-
tention symptoms (ADHD-RS-C) compared to boys might be an artefact related to the gender
specific cut-offs for normalisation based on a study conducted 10 years ago [55]. This point
toward a need for new age and gender specific norms for ADHD core symptom scores.
IQ above 85 versus IQ below or equal to 85 but above 70 (inferioritas intellectualis) was sta-
tistically significantly associated with a better chance of Nor/Bnor of the inattention and
hyperactivity-impulsivity symptoms, whereas the weekly reduction of sum scores of inatten-
tion and of hyperactivity-impulsivity showed no differences between IQ groups. These seem-
ingly mixed results might indicate equally beneficial effects in both groups even though the
chance of normalization is reduced when IQ is reduced.
Having two or more comorbid psychiatric diagnoses predicted a better chance of normali-
sation or borderline normalisation of hyperactivity-impulsivity symptoms (Nor/Bnor of
ADHD-RS-C), but this finding contrasted with the statistical modelling of the course of hyper-
activity-impulsivity symptoms, which showed no significant association with comorbidity.
Results from the Multimodal Treatment Attention Deficit Hyperactivity Disorder (MTA)
study [82] showed that patients with an intelligence level above the population mean (IQ 100)
had a better response to MPH treatment than patients with lower IQ. Other RCTs also found a
normal IQ range is a predictor for a good treatment outcome [83–85], which also was found in
one naturalistic observational study [86] but not in another [87]. Many different baseline char-
acteristics have been sporadically identified as predictors for good treatment response (and
sometimes opposite directed) in RCTs [82, 85] and naturalistic observational studies [30, 87].
The most consistent result of a predictor for a good treatment outcome might be intelligence
within in the normal to upper range.It is well known that ARs of MPH are related to high
doses of MPH as observed in RCTs [78, 88] and in a naturalistic observational study [34], but a
review of 10 RCTs did not find the same association [80]. Severe global impairment (CGI-S
6–7) in week 0 predicted a higher mean problem score of ARs (BSSERS-C) throughout the
whole treatment period including week 0, and severe global impairment (CGI-S 6–7) in week
0 was associated with a high end-dose of IR-MPH. Taken together, these findings indicate that
the more severely ill patients with more severe symptoms mimicking ARs before initiation of
treatment end up needing higher end-doses of MPH. It is important to notice that the ARs
measured by the BSSERS-C may be ‘influenced’ by the global impairment level (CGI-S) of a
patient. In this study, CGI-S proved to be a useful psychometric instrument, which confirmed
its wide applicability in the psychiatry for measuring global impairment.
Strength and limitations
The main strength of the study was the inclusion of a consecutive clinical and representative
sample of children in their first medical treatment for ADHD in a ‘real-life setting’. Moreover,
the children were recruited from a well-defined catchment area, and the diagnosis of ADHD
was based on best practice and routine examination using standardised instruments [29]. The
included children represent a typical population of children with ADHD and one or several
comorbid mental disorders, and with moderate to severe global impairment [89].
The clinical investigator performed all the weekly assessments of the same group of patients
throughout the 12-week study period and monitored the IR-MPH treatment effects jointly
with the clinician. Furthermore, the outcome measures of ADHD core symptoms were based
on consensus ratings of all psychometric instruments in week 0 and 12. The intensive
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monitoring of symptom reductions, ARs, and the careful titration of IR-MPH probably
explains the low attrition rate.
The limitations of this observational study included lack of a control condition. Further-
more, the assessors could not be blinded to dose of MPH, because the dosing was individually
titrated based on the weekly assessments of child’s effects and ARs. Therefore, the symptom
reductions of ADHD core symptoms and ARs due to IR-MPH treatment cannot be differenti-
ated from the natural course of ADHD with a regression toward the mean and determination
of the effect of the frequent contact with the clinical investigator. It can also be difficult to define
a relevant cut-off for Nor or Bnor of ADHD core symptoms, and information might be lost
when continuous variables (the ADHD sum scores) are dichotomised into cut-off values [90].
The study determined Nor and Bnor based on Inattention and Hyperactivity-Impulsivity of
ADHD-RS-C using the existing Danish norms and cut-off values for ADHD-RS-P instead of
the foreign norms and values for ADHD-RS-C [55, 63]. The WFIRS-P and TOVA are widely
used but have not been validated in Denmark. The raw scores of TOVA were converted to z-
scores based on week 0 total raw scores. BSSERS has no instructions for how to rate each item
from 0 (problem absent) to 9 (problem evokes serious impairment) [49]. To overcome this, the
authors of this study created a manual for ratings of the 17 items of BSSERS-C. Furthermore,
the discriminative validity of BSSERS-C with regard to various mental and physical health
problems and ARs are not known, and BSSERS-C has not been validated in Denmark.
The study was a short-term study which is a limitation. The extent to which the individually
monitored long-term MPH treatment can improve the prognosis is sparsely elucidated. The
efficacy of pharmacological treatment of ADHD in RCTs are often using fixed doses and short
follow up time periods (<six month), whereas the long-term treatment effects are limited stud-
ied [15, 81]. But new long-term cohort studies have found pharmacological treatment associ-
ated to lower risk of accidents [91, 92], criminality [93], suicides [94], and better academical
performance [22, 23, 95].
Perspectives for the daily clinic
This study showed no causal relationship between baseline characteristics and symptom
reductions or ARs of IR-MPH. Most patients continued treatment throughout the 12-weeks.
The treatment outcome showed a favourable balance between symptom reductions and ARs.
This is assuring compared to the recent debate of the efficacy of MPH [96, 97]. Our study also
emphasizes that the clinicians should obtain baseline information about severity of ADHD
symptoms and potential ARs, and they should continuously monitor these during up-titration
of MPH using standardised rating scales. The BSSERS proved ineffective because it may not
differentiate between symptoms and ARs, and there is an urgent need for development of a
better instrument to monitor ARs of MPH in clinical practice. The parents seemed to be more
aware of the severity of the patients’ ADHD core symptoms than the teachers. Patients with
severe global levels of symptoms and functional impairments appear to report more severe
symptoms mimicking ARs before initiation of treatment and during the treatment period.
Research perspectives
Future studies should investigate the importance of thorough individually titrated dosing of
MPH, monitored on standard rating scales of ADHD core symptoms and ARs, and the effect
of frequent brief contact with a clinician (e.g., a nurse) during the titration period. This will be
important knowledge for the standard treatment of ADHD.
This study suggests an alignment of ways to measure and define a clinical response to MPH
on a standard ADHD-rating scale and more valid methods to monitor ARs.
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Studies of effects and adverse reactions to long-term treatment with methylphenidate are
warrened as these observations are lacking in the literature.
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